Drugs / fenticonazole
fenticonazole
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05361369 | May 2022 | — | Exeltis Turkey | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06056947 | Jul 2020 → May 2021 | bacterial vaginosis, trichomonal vulvovaginitis, vulvovaginal candidiasis | Ege University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fenticonazole | “The study drug, EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule, is a fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine.” NCT05361369 ↗1“EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)” NCT06056947 ↗ |
| Known as | Fenticonazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1651990 ↗ |
| Known as | Gynoxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1651990 ↗ |
| Modality | Small molecule | — CHEMBL1651990 ↗ |
| Route | Other | “following intravaginal administration of this fixed-dose combination.” NCT05361369 ↗ |